South Korean medical aesthetics manufacturer Hugel reported its strongest quarterly performance ever, with second-quarter revenue reaching ₩110.3 billion ($79.48 million) and operating profit climbing to ₩56.7 billion ($40.81 million). The figures represent year-over-year increases of 15.5% and 33.6%, respectively.
For the first half of 2025, Hugel’s cumulative sales rose 17.9% to ₩200 billion ($144.0 million), marking the first time the Chuncheon-based company has crossed that threshold for a six-month period. Operating profit for the half-year jumped 44% to ₩95 billion ($68.4 million).
The gains were driven largely by overseas demand for Hugel’s botulinum toxin and hyaluronic acid filler products, with exports accounting for 63% of total quarterly sales. International sales of these core products increased 21% year-over-year to ₩69.8 billion ($50.2 million).
Hugel’s cosmetics division showed particularly aggressive growth, with revenue surging 105% to ₩13.6 billion ($9.8 million) in the second quarter, though this remains a smaller segment compared to its medical aesthetics business.
The company, which manufactures products sold under brands including Botulax and Letybo, has regulatory approvals in major markets including the United States, China, and Europe. However, competition in the global medical aesthetics market continues to intensify as established players defend market share.
Hugel cited plans to deepen its U.S. market penetration and expand in emerging markets, according to company officials.
